

ONCHOCERCIASIS

GUIDELINES FOR STOPPING MASS DRUG
ADMINISTRATION AND VERIFYING
ELIMINATION OF HUMAN ONCHOCERCIASIS



**CRITERIA AND
PROCEDURES**

ONCHOCERCIASIS

GUIDELINES FOR STOPPING
MASS DRUG ADMINISTRATION
AND VERIFYING ELIMINATION OF
HUMAN ONCHOCERCIASIS

CRITERIA AND PROCEDURES



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures.

1.Onchocerciasis – prevention and control. 2.Onchocerciasis – epidemiology. 3.Onchocerciasis - drug therapy. 4.Ivermectin - administration and dosage. 5.Onchocerca volvulus - isolation & purification. 6.Guideline. I.World Health Organization.

ISBN 978 92 4 151001 1

(NLM classification: WC 885)

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.


All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland.

WHO/HTM/NTD/PCT/2016.1

Guidelines update date: 2020

CONTENTS



GUIDELINES FOR STOPPING MASS DRUG ADMINISTRATION AND VERIFYING ELIMINATION OF HUMAN ONCHOCERCIASIS

CRITERIA AND PROCEDURES

ACKNOWLEDGEMENTS	vi
GLOSSARY	vii
EXECUTIVE SUMMARY	x
1 BACKGROUND	1
1.1 Introduction.....	1
1.2 Control and elimination of human onchocerciasis.....	1
1.3 Onchocerciasis elimination programmes and their phases.....	2
1.4 Description of diagnostic tests.....	4
1.4.1 Entomological evaluation by O-150 PCR.....	4
1.4.2 Serological evaluation by Ov-16.....	5
1.4.3 Parasitological evaluation by skin snip microscopy and DEC patch test.....	6
1.4.4 Skin snip evaluation by PCR.....	6

2	RATIONALE	7
3	PURPOSE AND OBJECTIVES.....	8
4	TARGET AUDIENCE.....	9
5	METHODS	10
5.1	Development process.....	10
5.2	Guideline questions.....	10
5.3	Systematic review.....	11
5.4	Formulation of recommendations.....	12
6	DECLARATION AND MANAGEMENT OF INTERESTS.....	13
7	RESULTS OF EVIDENCE RETRIEVAL, SYNTHESIS AND ASSESSMENT	14
8	RECOMMENDATIONS.....	15
8.1	Demonstration of the interruption of transmission of <i>Onchocerca volvulus</i> for the purpose of stopping MDA.....	15
8.1.1	O-150 PCR (Poolscreen) testing in black flies.....	15
8.1.2	Ov-16 serology testing in children less than 10 years of age.....	16
8.1.3	Skin snip microscopy.....	18
8.1.4	Ocular infection	19
8.2	Confirmation of interruption of transmission of <i>Onchocerca volvulus</i> at the end of post-treatment surveillance.....	20
8.2.1	O-150 PCR (Poolscreen) testing in black flies.....	20
8.2.2	Ov-16 serology testing in children less than 10 years of age.....	20
8.2.3	Ocular infection	21
9	STANDARD OPERATING PROCEDURES FOR STOPPING MASS DRUG ADMINISTRATION AND VERIFYING ELIMINATION.....	22
9.1	Introduction.....	22
9.2	Post-treatment surveillance (phase 2).....	22
9.2.1	Step 1	22
9.2.2	Step 2	22
9.2.3	Step 3	25
9.2.4	Step 4	25
9.3	The international verification team.....	25
9.4	Acknowledgement of elimination.....	25
9.5	Conclusion	26
10	POST-ELIMINATION SURVEILLANCE (PHASE 3).....	27

11 FUTURE CONSIDERATIONS	28
11.1 Revision	28
11.2 Modelling	28
12 DISSEMINATION AND EVALUATION OF THE EFFECT OF IMPLEMENTING THE GUIDELINES	29
REFERENCES	30
ANNEXES (SEE SEPARATE FILE)	
Annex 1. Key questions	1
Annex 2. Summary of the evidence	5
Annex 3. Decision tables.	95
3.1. O-150 PCR (Poolscreen) testing in black flies (KQ1).....	95
3.2 . Ov-16 serology (KQ1)	105
3.3. skin snip microscopy (KQ1)	115
3.4. ocular infection (KQ1).....	125
3.5. O-150 PCR (Poolscreen) testing in black flies (KQ2).....	125
3.6. Ov-16 serology (KQ2)	143
3.7. ocular infection (KQ2).....	153
Annex 4. Summary of declared interests.....	161
Annex 5. Preparation of the country report	163
Annex 6. Process of verification of elimination and role and responsibilities of the international verification team	167
6.1. The process of verification.....	167
6.2 . The international verification team.....	167
6.3. The country visit	168
6.4. The report of the international verification team.....	169
Annex 7. Entomological evaluation of the impact of community-wide ivermectin distribution on <i>Onchocerca volvulus</i> transmission	171
7.1. General remarks	171
7.2 . Methodology.....	172
7.3 . Data reporting and analysis	173

ACKNOWLEDGEMENTS

Overall coordination and writing of the guidelines

Tony Ukety coordinated the development and drafting of the guidelines with input from Gautam Biswas, under the overall direction of Dirk Engels.

WHO Guideline Development Group

Eddie Cupp (Emeritus Professor, Auburn University, United States of America), Yankum Dadzie (formerly of the Onchocerciasis Control Programme in West Africa and the African Programme for Onchocerciasis Control, Ghana); Patrick Lammie (United States Centers for Disease Control and Prevention, and Task Force for Global Health, United States of America); David Molyneux (Liverpool School of Tropical Medicine, United Kingdom of Great Britain and Northern Ireland); Thomas Unnasch (University of South Florida, United States of America); Laurent Yameogo (formerly of the Onchocerciasis Control Programme in West Africa and the African Programme for Onchocerciasis Control, Burkina Faso).

WHO Steering Group

Gautam Biswas (Department of Control of Neglected Tropical Diseases); Daniel Boakye (African Programme for Onchocerciasis Control); Albis Gabrielli (Department of Tropical Diseases and Zoonoses, Eastern Mediterranean Regional Office); Chris Mwikisa (African Programme for Onchocerciasis Control); Tony Ukety (Department of Control of Neglected Tropical Diseases).

Co-chairs of the WHO Guideline Development Group

Elie Akl (American University of Beirut, Lebanon); Mark Eberhard (retired staff, United States Centers for Disease Control and Prevention).

GRADE methodologists of the WHO Guideline Development Group

Gerald Gartlehner (Danube University Krems, Austria); Peter Mählknecht (Danube University Krems, Austria); Kylie Thaler (Danube University Krems, Austria).

Peer reviewers

Steven Ault (Neglected Infectious Diseases, WHO Regional Office for the Americas); Darin Evans (United States Agency for International Development); V. Kumaraswami (retired scientist, Indian Council of Medical Research, India); Richard Ndyomugenyi (former Onchocerciasis Elimination Programme Manager, Ministry of Health, Uganda).

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27162

